Clinical trial
TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL)
NCT00368264 · Medical University of Vienna, Other · Terminated
Key facts
| NCT number | NCT00368264 |
|---|---|
| Title | TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ) |
| Official title | A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNF-alpha Chimeric Monoclonal Antibody (Infliximab) and Azathioprine in Patients Suffering From Systemic Lupus Erythematosus (SLE) With WHO Class V Glomerulonephritis |
| Lead sponsor | Medical University of Vienna, Other |
| Collaborators | Hospital Hietzing Medical University of Graz Charite University, Berlin, Germany University of Erlangen-Nürnberg Heinrich-Heine University, Duesseldorf University Medical Center Groningen Leiden… |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Lupus Erythematosus, Systemic, Lupus Nephritis |
| Intervention type | Drug |
| Interventions | infliximab, placebo |
| Enrollment | 1 |
| Start date | Sep 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Aug 24, 2006 |
| Last update posted | Oct 5, 2009 |
| Countries | Austria, Germany, Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: